Cargando…

Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea

OBJECTIVE: Although severe obstructive sleep apnea (OSA) is an important risk factor for atherosclerosis-related diseases including coronary artery disease (CAD), there is no reliable biomarker of CAD risks in patients with OSA. This study aimed to test our hypothesis that circulating autoantibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumura, Takuma, Terada, Jiro, Kinoshita, Taku, Sakurai, Yoriko, Yahaba, Misuzu, Tsushima, Kenji, Sakao, Seiichiro, Nagashima, Kengo, Ozaki, Toshinori, Kobayashi, Yoshio, Hiwasa, Takaki, Tatsumi, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875805/
https://www.ncbi.nlm.nih.gov/pubmed/29596467
http://dx.doi.org/10.1371/journal.pone.0195015
_version_ 1783310415962308608
author Matsumura, Takuma
Terada, Jiro
Kinoshita, Taku
Sakurai, Yoriko
Yahaba, Misuzu
Tsushima, Kenji
Sakao, Seiichiro
Nagashima, Kengo
Ozaki, Toshinori
Kobayashi, Yoshio
Hiwasa, Takaki
Tatsumi, Koichiro
author_facet Matsumura, Takuma
Terada, Jiro
Kinoshita, Taku
Sakurai, Yoriko
Yahaba, Misuzu
Tsushima, Kenji
Sakao, Seiichiro
Nagashima, Kengo
Ozaki, Toshinori
Kobayashi, Yoshio
Hiwasa, Takaki
Tatsumi, Koichiro
author_sort Matsumura, Takuma
collection PubMed
description OBJECTIVE: Although severe obstructive sleep apnea (OSA) is an important risk factor for atherosclerosis-related diseases including coronary artery disease (CAD), there is no reliable biomarker of CAD risks in patients with OSA. This study aimed to test our hypothesis that circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1-Abs) are associated with the prevalence of CAD in patients with OSA. METHODS: Eighty-two adults diagnosed with OSA by polysomnography, 96 patients with a diagnosis of acute coronary syndrome (ACS) and 64 healthy volunteers (HVs) were consecutively enrolled. Serum samples were collected from patients with OSA at diagnostic polysomnography and from patients with ACS at disease onset. Serum NBL1-Ab level was measured by amplified luminescence proximity homogeneous assay and its association with clinical variables related to atherosclerosis was evaluated. RESULTS: NBL1-Ab level was significantly elevated in patients with both OSA and ACS compared with HVs. Subgroup analyses showed that NBL1-Ab level was markedly higher in patients with severe OSA and OSA patients with a history of CAD. Weak associations were observed between NBL1-Ab level and apnea-hypopnea index, age, mean SpO(2) and arousal index, whereas significantly higher NBL1-Ab levels were observed in OSA patients with a history of CAD than in those without a history of CAD. Sensitivity analysis using a logistic regression model also demonstrated that increased NBL1-Ab levels were associated with the previous history of CAD in patients with OSA. CONCLUSIONS: Elevated NBL1-Ab levels may be associated with the prevalence of CAD in patients with OSA, which needs to be confirmed further.
format Online
Article
Text
id pubmed-5875805
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58758052018-04-13 Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea Matsumura, Takuma Terada, Jiro Kinoshita, Taku Sakurai, Yoriko Yahaba, Misuzu Tsushima, Kenji Sakao, Seiichiro Nagashima, Kengo Ozaki, Toshinori Kobayashi, Yoshio Hiwasa, Takaki Tatsumi, Koichiro PLoS One Research Article OBJECTIVE: Although severe obstructive sleep apnea (OSA) is an important risk factor for atherosclerosis-related diseases including coronary artery disease (CAD), there is no reliable biomarker of CAD risks in patients with OSA. This study aimed to test our hypothesis that circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1-Abs) are associated with the prevalence of CAD in patients with OSA. METHODS: Eighty-two adults diagnosed with OSA by polysomnography, 96 patients with a diagnosis of acute coronary syndrome (ACS) and 64 healthy volunteers (HVs) were consecutively enrolled. Serum samples were collected from patients with OSA at diagnostic polysomnography and from patients with ACS at disease onset. Serum NBL1-Ab level was measured by amplified luminescence proximity homogeneous assay and its association with clinical variables related to atherosclerosis was evaluated. RESULTS: NBL1-Ab level was significantly elevated in patients with both OSA and ACS compared with HVs. Subgroup analyses showed that NBL1-Ab level was markedly higher in patients with severe OSA and OSA patients with a history of CAD. Weak associations were observed between NBL1-Ab level and apnea-hypopnea index, age, mean SpO(2) and arousal index, whereas significantly higher NBL1-Ab levels were observed in OSA patients with a history of CAD than in those without a history of CAD. Sensitivity analysis using a logistic regression model also demonstrated that increased NBL1-Ab levels were associated with the previous history of CAD in patients with OSA. CONCLUSIONS: Elevated NBL1-Ab levels may be associated with the prevalence of CAD in patients with OSA, which needs to be confirmed further. Public Library of Science 2018-03-29 /pmc/articles/PMC5875805/ /pubmed/29596467 http://dx.doi.org/10.1371/journal.pone.0195015 Text en © 2018 Matsumura et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Matsumura, Takuma
Terada, Jiro
Kinoshita, Taku
Sakurai, Yoriko
Yahaba, Misuzu
Tsushima, Kenji
Sakao, Seiichiro
Nagashima, Kengo
Ozaki, Toshinori
Kobayashi, Yoshio
Hiwasa, Takaki
Tatsumi, Koichiro
Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea
title Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea
title_full Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea
title_fullStr Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea
title_full_unstemmed Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea
title_short Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea
title_sort circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (nbl1): a potential biomarker for coronary artery disease in patients with obstructive sleep apnea
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875805/
https://www.ncbi.nlm.nih.gov/pubmed/29596467
http://dx.doi.org/10.1371/journal.pone.0195015
work_keys_str_mv AT matsumuratakuma circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT teradajiro circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT kinoshitataku circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT sakuraiyoriko circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT yahabamisuzu circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT tsushimakenji circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT sakaoseiichiro circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT nagashimakengo circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT ozakitoshinori circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT kobayashiyoshio circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT hiwasatakaki circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea
AT tatsumikoichiro circulatingautoantibodiesagainstneuroblastomasuppressoroftumorigenicity1nbl1apotentialbiomarkerforcoronaryarterydiseaseinpatientswithobstructivesleepapnea